AstraZeneca's Anemia Drug Sees Setback At FDA Committee
AstraZeneca has said a U.S. Food and Drug Administration advisory committee has overwhelmingly recommended against giving the green light to anemia drug roxadustat for people with chronic kidney ailments....To view the full article, register now.
Already a subscriber? Click here to view full article